India, April 8 -- Shares of Pluristem Therapeutics Inc. (PSTI) are surging over 33% in pre-market today, after the company announced preliminary data from its compassionate use program, treating seven patients suffering from acute respiratory failure and inflammatory complications associated with COVID-19 with Pluristem's PLX cells, in three medical centers in Israel.
Further, the company has planned to apply for initiation of a multinational regulated clinical trial program for the potential use of PLX cells in the treatment of patients suffering from complications associated with COVID-19.
The stock has been trading in the range of $2.82 - $7.30 for the past one year, and closed Monday's trade at $3.36, up 11 cents or 3.38%. PSTI is cur...